Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Circulating Biomarker in Malignant Melanoma
share announcement

Circulating Biomarker in Malignant Melanoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 4608

Special Issue Editor

Dr. Elin S. Gray

E-Mail Website
Guest Editor
School of Medical and Health Sciences, Edith Cowan University, Joondalup WA 6027, Australia
Interests: melanoma; uveal melanoma; circulating tumor cells; circulating tumor DNA; exosomes; platelets; immunotherapy; targeted therapy; genetic evolution; drug resistance; single cell-sequencing

Special Issue Information

Dear Colleagues,

Current protocols for prognostication, prediction, and monitoring of therapy response and relapse in melanoma patients often rely on invasive tumor biopsies, which provide valuable information on a single tumor at a single time point. There is an unmet need for blood-based tests to guide treatment decisions and monitoring of melanoma patients. This is particularly important as new adjuvant and neoadjuvant regimes are entering clinical practice.

Analysis of tumor biomarkers, such as circulating tumor DNA, circulating tumor cells, and tumor-derived extracellular vesicles, provides a window into features of the melanoma lesions that can inform patients' treatment and clinical management.

This Special Issue of Cancers aims to highlight new findings in the potential role of circulating biomarkers in enabling timely and accurate diagnosis, treatment, and assessment of therapeutic response in melanoma patients. We look forward to receiving manuscripts highlighting novel contributions to this rapidly evolving translational research field essential to improving melanoma outcomes.

Prof. Dr. Elin S. Gray
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • circulating tumor cells
  • circulating tumor DNA
  • exosomes
  • platelets
  • immunotherapy
  • targeted therapy
  • genetic evolution
  • drug resistance

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 12451 KiB  
Article
The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes Derived from the Serum of Uveal Melanoma Patients Reveals Potential Biomarkers of Disease Progression
by Joanna Patrycja Wróblewska, Michał Stefan Lach, Katarzyna Kulcenty, Łukasz Galus, Wiktoria Maria Suchorska, Daniel Rösel, Jan Brábek and Andrzej Marszałek
Cancers 2021, 13(13), 3334; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133334 - 02 Jul 2021
Cited by 14 | Viewed by 2114
Abstract
Background: Uveal melanoma (UM) is the most common intraocular tumour in adults with a poor prognosis and extremely high mortality rate due to the development of metastatic disease. However, despite relatively good knowledge about the histological and genetic risk factors for metastasis development, [...] Read more.
Background: Uveal melanoma (UM) is the most common intraocular tumour in adults with a poor prognosis and extremely high mortality rate due to the development of metastatic disease. However, despite relatively good knowledge about the histological and genetic risk factors for metastasis development, there is no specific biomarker that would allow early detection of UM progression. Recently, exosomes and their molecular cargo have been widely studied in the search for potential biomarkers in several cancers. The purpose of this study was to analyze the inflammation-related protein cargo of exosomes derived from the serum of primary and metastatic UM patients and healthy donors. Methods: The exosomes were isolated from the serum of primary and metastatic UM patients and healthy donors. Using multiplex immunoassay technology, we analyzed the concentration of 37 inflammation-related proteins in obtained exosomes. Results: The analysis of protein cargo showed several molecules related to inflammation, such as interferon-gamma, interleukin 2, 22 and 12(p40), Pentraxin-3, TNFSF13B and TNFSF8 which were significantly enriched in metastatic UM exosomes. We showed a significant correlation between the disease stage and the concentration of these inflammation-related proteins from exosomal cargo. Conclusions: Based on the obtained results, we propose the panel of exosomal proteins for early detection of uveal melanoma progression into metastatic disease. Full article
(This article belongs to the Special Issue Circulating Biomarker in Malignant Melanoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 502 KiB  
Review
Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients
by Yoshiaki Shoji, Matias A. Bustos, Rebecca Gross and Dave S. B. Hoon
Cancers 2022, 14(4), 859; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14040859 - 09 Feb 2022
Cited by 7 | Viewed by 1925
Abstract
Circulating tumor cells (CTCs) have been studied using multiple technical approaches for interrogating various cancers, as they allow for the real-time assessment of tumor progression, disease recurrence, treatment response, and tumor molecular profiling without the need for a tumor tissue biopsy. Here, we [...] Read more.
Circulating tumor cells (CTCs) have been studied using multiple technical approaches for interrogating various cancers, as they allow for the real-time assessment of tumor progression, disease recurrence, treatment response, and tumor molecular profiling without the need for a tumor tissue biopsy. Here, we will review studies from the last 15 years on the assessment of CTCs in cutaneous melanoma patients in relation to different clinical outcomes. The focus will be on CTC detection in blood samples obtained from cutaneous melanoma patients of different clinical stages and treatments utilizing multiple platforms. Assessment of multiple molecular melanoma-associated antigen (MAA) markers by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was the most common assay allowing for the improvement of assay sensitivity, tumor heterogeneity, and to predict patient outcomes. Multicenter studies demonstrate the utility of CTC assays reducing the bias observed in single- center trials. The recent development of CTC enrichment platforms has provided reproducible methods. CTC assessment enables both multiple mRNAs and DNAs genomic aberration profiling. CTC provides specific important translational information on tumor progression, prediction of treatment response, and survival outcomes for cutaneous melanoma patients. The molecular studies on melanoma CTCs have provided and may set standards for other solid tumor CTC analyses. Full article
(This article belongs to the Special Issue Circulating Biomarker in Malignant Melanoma)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop